Clinical Trial

A Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese Participants

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HM17321 after single and multiple ascending doses in healthy and obese participants.
Protocol Amendment History 4 changes
critical Primary endpoint(s) modified 2026-05-05
notable Enrollment increased: 40 -> 90 participants 2026-05-05
notable Primary completion pushed: 2026-04 -> 2027-03 2026-05-05
minor Completion pushed: 2026-04 -> 2027-03 2026-05-05
Trial Details
NCT Number NCT07219589
Lead Sponsor Hanmi Pharmaceutical Company Limited
Conditions Obesity, Obese
Enrollment 90 participants
Start Date 2025-11-06
Primary Completion 2027-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-05-04